Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00713791 · ClinicalTrials.gov registry record · Phase 1

Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.

A Phase 1 study of Healthy, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT00713791 is a Phase 1 study of Healthy that has completed, run by AstraZeneca. The registered enrollment target is 20 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00713791, a Phase 1 study of Healthy, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This study is designed to see how different formulations of ZD4054 (Zibotentan) are absorbed by the body. As for all clinical trials, safety and tolerability of the drug will be evaluated.

Conditions Studied

Interventions

  • DRUG ZD4054

Study Locations (1)

Pennsylvania

  • Research Site - Philadelphia

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2008-06
Est. Completion 2008-08
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT00713791

The ClinicalTrials.gov registry entry for NCT00713791 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which ZD4054 is the first listed.

NCT00713791 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00713791 about?

NCT00713791 is a clinical study titled "Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.". This study is designed to see how different formulations of ZD4054 (Zibotentan) are absorbed by the body. As for all clinical trials, safety and tolerability of the drug will be evaluated.

What is the current status of trial NCT00713791?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2008-06. Estimated completion is 2008-08.

What conditions does trial NCT00713791 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00713791?

The interventions under investigation include: ZD4054 (DRUG).

Who is sponsoring clinical trial NCT00713791?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00713791 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.